Adaptimmune Therapeutics PLC reports results for the quarter ended in March - Earnings Summary

Adaptimmune Therapeutics

09/05/2022 14:33

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported a
quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
March. The mean expectation of six analysts for the quarter was
for a loss of 22 cents per share.
    * Revenue rose 723.7% to $3.58 million from a year ago; 
analysts
expected $3.29 million. 
    * Adaptimmune Therapeutics PLC's reported EPS for the
quarter was
a loss of 30 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Adaptimmune Therapeutics PLC shares had fallen by 17.0%
this
quarter and lost 54.4% so far this year.
    * The company reported a quarterly loss of $50.27 million.
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $7.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated May 9 at 01:32 p.m.  ​All
figures in US dollars unless otherwise stated